Advertisement Pharmaceutical Business review - Page 1158 of 5274 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
May 26, 2026

Pierre Fabre’s Braftovi gains CHMP positive opinion for mCRC

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Pierre Fabre Laboratories’ Braftovi (encorafenib) for the treatment of metastatic colorectal cancer (mCRC) with BRAFV600E mutations.

In the Phase III trial, the combination improved progression-free survival statistically and clinically. Credit: Motortion Films / Shutterstock.com.